Notes

Cytotoxic Flavonol Glycosides from *Triplaris cumingiana*

Ahmed A. Hussein,[†,⊥] Icela Barberena,[†] Mireya Correa,[†] Phyllis D. Coley,[‡,§] Pablo N. Solis,[†] and Mahabir P. Gupta*[,†,‡]

Centro de Investigaciones Farmacognósticas de la Flora Panameña (CIFLORPAN), Facultad de Farmacia, Universidad de Panamá, Apartado 10767, Estafeta Universitaria, Panamá, República de Panamá, Smithsonian Tropical Research Institute, Box 2072, Panama, Republic of Panama, and Department of Biology, University of Utah, Salt Lake City, Utah 84112-0840

Received June 10, 2004

Three new compounds, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4*H*-chromen-3-yl-4,6-bis-*O*-β-D-(3,4,5-trihydroxybenzoyl)glucopyranoside (**1**), 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4*H*-chromen-3-yl-5-*O*-α-L-(3,4,5-trihydroxybenzoyl)arabinofuranoside (**2**), and 2-hydroxy-4-*O*-α-L-(3,5,7-trihydroxy-4-oxo-4*H*-chromen-2-yl)phenylarabinofuranoside (**3**), were isolated from the young leaves of *Triplaris cumingiana,* together with two known compounds, quercetin 3-*O*-α-L-(5″-*O*-galloyl)arabinofuranoside (**4**) and quercetin 3-*O*-β-D-(6″-*O*-galloyl)glucopyranoside (**5**). The structures of **1**−**3** were established by spectroscopic methods. Compounds **1**−**5** were evaluated for their cytotoxic activities against the MCF-7, H-460, and SF-268 human cancer cell lines.

As part of the Panama ICBG (International Cooperative Biodiversity Group) program aimed at discovering *inter alia* novel potential antitumor agents, an ethyl acetate-soluble extract of the young leaves of *Triplaris cumingiana* showed cytotoxic activity against the MCF-7, H-460, and SF-268 human cancer cell lines. The genus *Triplaris* (Polygonaceae) comprises approximately 20 species in South and Central America. *Triplaris cumingiana* Fisch. & C.A. Mey. ex Mey. is widely distributed in Panama[1] with no reports on this species having been found in the literature. Bioassay-guided fractionation of the EtOAc extract of *T. cumingiana* young leaves, using the MCF-7 (breast), H-460 (lung), and SF-268 (CNS) human cancer cell lines for monitoring fractionation, afforded three new compounds, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4*H*-chromen-3-yl-4,6-bis-*O*-β-D-(3,4,5-trihydroxybenzoyl)-glucopyranoside (**1**), 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4*H*-chromen-3-yl-5-*O*-α-L-(3,4,5-trihydroxybenzoyl)-arabinofuranoside (**2**), and 2-hydroxy-4-*O*-α-L-(3,5,7-trihydroxy-4-oxo-4*H*-chromen-2-yl)phenylarabinofuranoside (**3**). Also isolated were two known compounds, quercetin 3-*O*-α-L-(5″-*O*-galloyl)arabinofuranoside (**4**)[2] and quercetin 3-*O*-β-D-(6″-*O*-galloyl)glucopyranoside (**5**) (tellimoside).[3]

Compound **1** was obtained as a yellow amorphous powder. The HRFABMS of **1** showed a $[M + 1]^+$ peak at *m/z* 769.12477, corresponding to the molecular formula $C_{35}H_{28}O_{20}$. Absorption maxima at 267 and 359 nm in the UV spectrum were characteristic of a flavonol skeleton.[4] The ^1H and ^{13}C NMR spectra (see Table 1) showed signals attributable to quercetin, two gallate groups [two singlets, each integrating for two protons, at δ 7.07 (H-6‴ and H-2⁗), 6.92 (H-2‴ and H-6⁗), and two carbonyl signals at δ_C 168.7 and 168.3], and signals of a glucose unit. The



1 R_1 = OH R_2 = H R_3 = *O*-β-glc-4′′,6′′-digallate
2 R_1 = H R_2 = H R_3 = *O*-α-ara-5′′-gallate
3 R_1 = OH R_2 = O-α-ara R_3 = OH
4 R_1 = OH R_2 = H R_3 = *O*-α-ara-5′′-gallate
5 R_1 = OH R_2 = H R_3 = *O*-β-glc-6′′-gallate

occurrence of a glucose unit was confirmed by acid hydrolysis and co-TLC with a reference sample. The above data indicated the presence of a quercetin glucoside esterified with two gallic acid units. The coupling constant of the anomeric proton ($J = 7.8$ Hz) and the ^{13}C NMR data indicated a β-glucopyranoside substituent. Substitution of the glucose unit at C-3 was indicated by the HMBC correlations between H-1″/C-3. The two gallate groups were positioned at C-4″ and C-6″, as evidenced from HMBC correlations of H-4″ and H-6″ with the gallate carbonyls (δ_C 168.7, 168.3) and the low-field shifted signals of H-4″ and H-6″ at 5.17 and 4.20 ppm, respectively. Furthermore, the $^1H-^1H$ COSY spectrum demonstrated correlations of H-4″/H-5″, H-3″ and H-6″/H-5″. On the basis of the above data, the structure of the new compound **1** was assigned as 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4*H*-chromen-3-yl-4,6-bis-*O*-β-D-(3,4,5-trihydroxybenzoyl)glucopyranoside.

Compound **2** was isolated as an amorphous yellow powder. The molecular formula of **2** was established as $C_{27}H_{22}O_{14}$ by HRFABMS. The UV spectrum in different shift reagents again indicated the presence of a flavonol skeleton.[4] The ^1H and ^{13}C NMR data of **2** (see Table 1) showed signals of kaempferol aglycone, a gallate group, and arabinose, which was supported by acid hydrolysis and co-TLC with all three reference compounds. The coupling constant of the anomeric proton ($J = 0.9$ Hz) and a careful

* To whom correspondence should be addressed. Tel: (507) 269-7655. Fax: (507) 264-0789. E-mail: cytedqff@ancon.up.ac.pa.
† Universidad de Panamá.
‡ Smithsonian Tropical Research Institute.
§ University of Utah.
⊥ Present address: Pharmacognosy and Chemistry of Medicinal Plants Laboratory, National Research Center, Dokki, Cairo, Egypt.

10.1021/np049803g CCC: $30.25
Published on Web 01/14/2005

Table 1. ^{13}C and ^{1}H NMR Data (δ values) of Compounds **1**−**3**[a]

	1		**2**		**3**	
position	δ_C	δ_H	δ_C	δ_H	δ_C	δ_H
2	160.1 s		157.6 s		159.3 s	
3	136.0 s		134.2 s		135.7 s	
4	179.9 s		179.8 s		180.8 s	
5	163.5 s		160.6 s		163.8 s	
6	100.7 d	6.15 d (2.3)	99.3 d	6.27 d (2.0)	100.7 d	6.22 d (2.0)
7	166.5 s		164.9 s		166.8 s	
8	95.7 d	6.30 d (2.3)	94.3 d	6.50 d (2.0)	95.6 d	6.41 d (2.0)
9	159.0 s		158.1 s		160.1 s	
10	106.3 s		105.1 s		106.4 s	
1′	124.4 s		122.1 s		123.9 s	
2′	118.0 d	7.58 d (1.5)	116.1 d	8.04 d (8.7)	117.7 d	7.52 d (2.2)
3′	147.2 s		131.3 d	7.03 d (8.7)[c]	147.1 s	
4′	150.4 s		132.6 s		150.6 s	
5′	116.7 d	6.73 d (9.3)	131.3 d	7.03 d (8.7)[c]	117.2 d	6.92 d (8.5)
6′	123.7 d	7.60 dd (9.0, 1.5)	116.1 d	8.04 d (8.7)	123.8 d	7.52 dd (8.5, 2.2)
1″	104.9 d	5.35 d (7.8)	108.9 d	5.62 d (0.9)	110.3 d	5.48 s
2″	76.7 d	3.86[b]	84.7 d	4.05 m	84.1 d	4.35 dd (3.0, 1.1)
3″	74.5 d	3.86[b]	78.8 d	4.03 m	79.5 d	3.92 dd (6.0, 3.0)
4″	73.0 d	5.17 t (9.8)	84.9 d	4.42 m	88.7 d	3.89 m
5″	74.5 d	3.70 t (9.8)	64.2 t	4.26 dd (11.8, 4.1)	63.4 t	3.51 m
6″	64.3 t	4.20 m				
1‴	121.9 s		121.1 s			
2‴, 6‴	111.2 d	7.07 s	109.9 d	7.06 s		
3‴, 5‴	146.7 s		145.6 s			
4‴	140.8 s		138.5 s			
CO	168.7 s		166.8 s			
1⁗	121.8 s					
2⁗, 6⁗	111.1 d	6.92 s				
3⁗, 5⁗	146.5 s					
4⁗	140.5 s					
CO	168.3 s					

[a] Compounds **1** and **3** measured in MeOD and compound **2** in acetone-d_6. Coupling constants are (J in Hz) in parentheses. Assignments were made on the basis of $^{1}H-^{1}H$-COSY, HMQC, and HMBC. Multiplicities were determined by DEPT 135 experiment. [b,c] Overlapping signals.

analysis of the ^{13}C NMR data[5−8] in addition to the NOESY correlations between H-1″/H-3″, H-4″ indicated the presence of an α-arabinofuranoside unit. Attachment of the arabinose at C-3 was deduced from the HMBC correlations between H-1″/C-3. The gallate group was positioned at C-5″, as evidenced from the low-field shifted H-5″ signal at 4.26 ppm and the HMBC correlation of H-5″ with the carbonyl carbon at δ_C 166.8 of the gallate unit. Thus, **2** was assigned as the new compound 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4*H*-chromen-3-yl-5-*O*-α-L-(3,4,5-trihydroxybenzoyl)arabinofuranoside.

The molecular formula of **3** was established by HR-FABMS as $C_{20}H_{18}O_{11}$. The UV spectrum and the results of acid hydrolysis, in addition to the ^{1}H and ^{13}C NMR data (see Table 1), indicated the presence of quercetin as the aglycone attached to an arabinose unit. The position of the arabinose substituent at C-4′ was evidenced from UV spectra run in different shift reagents and the HMBC correlation between H-1″/C-4′. Thus, **3** was assigned as 2-hydroxy-4-*O*-α-L-(3,5,7-trihydroxy-4-oxo-4*H*-chromen-2-yl)phenylarabinofuranoside.

Compound **4** was identified as quercetin 3-*O*-α-L-(5″-*O*-galloyl)arabinofuranoside[2] and compound **5** as quercetin 3-*O*-β-D-(6″-*O*-galloyl)glucopyranoside (tellimoside),[3] by comparison of their spectral data reported in the literature.

Table 2 shows the GI_{50} values of compounds **1**−**5** when tested against a panel of three cell lines. Compound **1** showed cytotoxic activity against the H-460 (lung) cell line (GI_{50} = 3 μg/mL), while compound **4** was active against all three cell lines [GI_{50} = 1.4, 1.2, and 2.3 μg/mL in MCF-7, H-460, and SF-268, respectively]. Table 2 also shows the more potent activity of quercetin 3-*O*-α-L-arabinofuranoside-5″-gallate (**4**) in comparison with quercetin 3-*O*-β-D-glucopyranoside-6″-gallate (**5**), which may indicate the effect of the presence of an arabinose substituent relative to glucose.

Table 2. Cytotoxic Activities of Compounds **1**−**5**[a]

	GI_{50} (μg/mL)		
compound	MCF-7	H-460	SF-268
1	>10	3.0	>10
2	9.0	>10	>10
3	9.1	7.3	>10
4	1.4	1.2	2.3
5	>10	>10	>10
adriamycin	6.2×10^{-7}	3.6×10^{-7}	5.3×10^{-7}

[a] For the cell lines used, see the Experimental Section.

Experimental Section

General Experimental Procedures. Melting points are uncorrected. Optical rotations were measured with a Perkin-Elmer 141 polarimeter. UV spectra were measured with a Perkin-Elmer Model Lambda 2 UV/vis spectrometer. IR spectra were recorded on a Perkin-Elmer 1310 spectrophotometer. NMR spectra were recorded using a Brüker Avance 300 spectrometer in acetone-d_6 or MeOD at 300 MHz for ^{1}H and 75.0 MHz for ^{13}C NMR. Mass spectra were obtained on a Kratos MS50TC mass spectrometer. Silica gel [Merck, Kieselgel 60 (0.063−0.200 mm) and (0.015−0.040 mm)], LiChroprep RP-18 [prepacked column size B (31 × 2.5 cm), 40−63 μm, Merck, 9303], and Sephadex LH-20 (Sigma, 904-37-6) were used for column chromatography. Silica gel plates (Merck, Kieselgel 60 F_{254s}) were used for TLC. β-D-Glucose (Sigma) and α-L-arabinose (Sigma) were used as reference compounds.

Plant Material. Young leaves of *T. cumingiana* were collected from Soberania National Park (N 9°14′26″, W 79°39′30″), in Panama, November 2002. Voucher specimens

(52304) are deposited in the Herbarium of the University of Panama (PMA).

Cytotoxicity Bioassay. The cytotoxic activity was determined against breast (MCF-7), lung (H-460), and central nervous system (SF-268) human cancer cell lines according to the method given by Monks et al.[9] During the isolation process, the activity of all fractions was monitored using the three cell lines. Adriamycin was used as reference compound.

Extraction and Isolation. Fresh young leaves of *T. cumingiana* (280 g) were extracted and subjected to solvent partitioning in a manner described before.[10] Briefly, fresh young leaves of *T. cumingiana* were homogenized in MeOH for 30 s in a Waring blender followed by treatment with a Polytron homogenizer (Brinkmann Instruments). After filtration, the mark was washed with EtOAc. The crude MeOH/EtOAc extract [(25.99 g; GI_{50} >10 μg/mL (MCF-7), 10 μg/mL (H-460), and 1.8 μg/mL (SF-268)] was partitioned between CH_2Cl_2 and H_2O, and the aqueous layer was further partitioned with EtOAc. The activity was retained in the EtOAc phase [5.8 g; percentage of growth (%G) 44.0, 42.1, and 39.7 of MCF-7, H-460, and SF-268, respectively]. Chromatography on a C_{18}-RP Lobar column using MeOH/H_2O as solvent (1:1, 2000 mL) yielded two fractions (1; 450 mL, 2; 1550 mL). Tannins and sugars were eluted in fraction 1, which was not cytotoxic. Fraction 2 (1.5 g; %G, 40.0, 36.7, 46.2) containing flavonoids was chromatographed on a C_{18}-RP Lobar column using as solvent system MeOH/H_2O (6:4, 1500 mL), which afforded fractions A (50−300 mL, 200 mg), B (350−600 mL, 162 mg), C (700−800 mL, 132 mg), and D (900−1500 mL, 250 mg), respectively. Fraction A was chromatographed separately on a Sephadex LH-20 column (60 × 2.5 cm) using 10% aqueous EtOH (500 mL), collecting 30 mL of each fraction, and combined fractions 4−7 yielded **4** (15 mg, 0.0053%). Fraction B was chromatographed under the same conditions as above, with combined fractions 2−4 affording **1** (20 mg, 0.0071%). Fraction D was chromatographed as above, and combined fractions 6−8 yielded **3** (50 mg, 0.01785%). Fraction C was also chromatographed as above, and fractions 2−4 yielded **2** (10 mg, 0.00357%), while fractions 5−7 yielded **5** (8 mg, 0.00285%).

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4*H*-chromen-3-yl-4,6-bis-*O*-β-D-(3,4,5-trihydroxybenzoyl)glucopyranoside (1): yellow amorphous powder, $[\alpha]^{28}_D$ +3.6° (*c* 0.14, MeOH); UV (MeOH) λ_{max} (log ϵ) 267 (4.71), 359 (4.39) nm; (MeOH + NaOMe) 273, 325, 410 nm; (MeOH + $AlCl_3$) 267, 300, 381 nm; (MeOH + $AlCl_3$ + HCl) 270, 290 (sh), 361, 405 nm; (MeOH + NaOAc) 267, 285 (sh), 359 nm; IR 3600−3000 (br), 1620, 1560, 1350, 1180 cm^{-1}; ^1H NMR (300 MHz, MeOD) and ^{13}C NMR (75 MHz, MeOD), see Table 1; FABMS *m/z* 769 $[M + 1]^+$ (3), 613 (3), 460 (3), 391 (3), 307 (25), 235 (3), 219 (3), 154 (100), 136 (66); HRFABMS *m/z* 769.12477 $[M + H]^+$ (calcd for $C_{35}H_{29}O_{20}$, 769.12522).

5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4*H*-chromen-3-yl-5-*O*-α-L-(3,4,5- trihydroxybenzoyl)arabinofuranoside (2): yellow amorphous powder; $[\alpha]^{28}_D$ −98.3° (*c* 0.06, MeOH); UV (MeOH) λ_{max} (log ϵ) 267 (4.00), 345 (3.76) nm; (MeOH + NaOMe) 274, 321, 390 nm; (MeOH + $AlCl_3$) 274, 300, 345, 395 nm; (MeOH + $AlCl_3$ + HCl) 274, 345, 390 nm; (MeOH + NaOAc) 267, 345 nm; ^1H NMR (300 MHz, acetone-d_6) and ^{13}C NMR (75 MHz, $CDCl_3$), see Table 1; FABMS *m/z* 769 $[M + 1]^+$ (3), 613 (3), 460 (3), 391 (3), 307 (25), 235 (3), 219 (3), 154 (100), 136 (66); HRFABMS *m/z* 571.11206 $[M + H]^+$ (calcd for $C_{27}H_{23}O_{14}$, 571.10878).

2-Hydroxy-4-*O*-L-(3,5,7-trihydroxy-4-oxo-4*H*-chromen-2-yl)phenylarabinofuranoside (3): yellow amorphous powder; $[\alpha]^{28}_D$ −106.3° (*c* 0.08, MeOH); UV (MeOH) λ_{max} (log ϵ) 256 (4.43), 360 (4.34) nm; (MeOH + NaOMe) 272, 325 (sh), 400 nm; (MeOH + $AlCl_3$) 274, 300 (sh), 425 nm; (MeOH + $AlCl_3$ + HCl) 268, 300 (sh), 362, 424 nm; (MeOH + NaOAc) 264, 397 nm; ^1H NMR (300 MHz, MeOD) and ^{13}C NMR (75 MHz, MeOD), see Table 1; FABMS *m/z* 435 $[M + 1]^+$ (4), 391 (10), 303 (10), 185 (61), 149 (10), 115 (10), 93 (100); HRFABMS *m/z* 435.09184 $[M + H]^+$ (calcd for $C_{20}H_{19}O_{11}$, 435.09274).

Acid Hydrolysis of 1−3. Five to 10 milligrams of each compound was added to 10% H_2SO_4 (5 mL) and left overnight at room temperature with stirring. The resulting reaction mixtures were neutralized and partitioned with EtOAc. The aqueous layers were freeze-dried using (Labconco), and the residues were dissolved in MeOH and co-TLC with authentic sugars β-D-glucose (Sigma) and α-L-arabinose (using silica gel, EtOAc/H_2O/formic acid/acetic acid (100:27:11:11), detection 10% H_2SO_4 in EtOH). Acid hydrolysis of **1**−**3** gave quercetin gallic acid and β-D-glucose (R_f 0.18), kaempferol, gallic acid and arabinose (R_f 0.25), and quercetin and α-L-arabinose, respectively.

Acknowledgment. This work was supported by a grant from the ICBG project entitled "Ecologically Based Bioprospecting in Panama" (1U01-TW01021-01), from the National Institutes of Health (NIH), National Science Foundation (NSF), and U.S. Department of Agriculture (USDA) to P.D.C. Special thanks are accorded to the Organization of American States for supporting project SEDI/AICD/AE 106/3 and to the National Environment Authority of Panama for authorizing plant collections. We also thank Dr. G. M. Cragg, of the U.S. National Cancer Institute, for the donation of cell lines. We also thank Dr. W. H. Gerwick, of Oregon State University, for running mass spectra.

References and Notes

(1) Woodson, R. F.; Shery, R. W. *Ann. Missouri Bot. Gard.* **1960**, *47*, 338−339.
(2) Kitanaka, S.; Matsuzaki, K. Jpn. Kokai Tokkyo Koho: JP 2001316398 A2 20011113, 2001.
(3) Collins, F. W.; Bohm, B. A.; Wilkins, C. K. *Phytochemistry* **1975**, *14*, 1099−1102.
(4) Mabry, T. J.; Markham, K. R.; Thomas, B. M. *The Systematic Identification of Flavonoids*; Springer: New York, 1970; Chapter 5, pp 39−61.
(5) Yasukawa, K.; Ogawa, H.; Takido, M. *Phytochemistry* **1990**, *5*, 1707−1708.
(6) Iwagawa, T.; Kawasaki, J.-I.; Hase, T.; Sako, S.; Okubo, T.; Ishida, M.; Kim, M. *Phytochemistry* **1990**, *29*, 1013−1014.
(7) Markham, K. R.; Andersen, Ø. M. *Phytochemistry* **1990**, *29*, 3919−3920.
(8) Markham, K. R.; Whitehouse, L. A.; Webby, R. F. *J. Nat. Prod.* **1987**, *50*, 660−663.
(9) Monks, A.; Scudiero, D. A.; Johnson, G. S.; Pauli, K. D.; Sausville, E. A. *Anticancer Drug Des.* **1997**, *12*, 533−541.
(10) Hussein, A. A.; Bozzi, B.; Correa, M.; Capson, T. L.; Kursar, T. A.; Coley P. D.; Solis, P. N.; Gupta, M. P. *J. Nat. Prod.* **2003**, *66*, 858−860.

NP049803G